Introduction {#S0001}
============

Nasal congestion, the uncomfortable sensation of nasal fullness, restriction, and/or draining, is a common phenomenon that plagues all of us at one time or another. Chronic or recurring nasal congestion, which affects between 10% and 20% of the global population, is a particularly troublesome experience associated with reduced quality of life, difficulty sleeping, reduced daytime performance, and increased health care utilization.[@CIT0001] It has been estimated that the financial impact of chronic nasal congestion is more than US \$5--10 billion annually.[@CIT0002],[@CIT0003]

The four pairs of air-filled paranasal sinuses have an anatomically unfavorable position in that they lie in proximity to the nasal cavity which is heavily colonized by bacteria, viruses, mold, and other environmental pathogens.[@CIT0004] Inflammation of the nasal mucosa can cause obstruction of the ostia, the small openings that connect the sinuses and nasal cavity, causing poor sinus ventilation, inadequate drainage, discomfort, and even infection.[@CIT0005] A myriad of products exist to manage the symptoms of nasal congestion, including pain relievers and anti-inflammatories, decongestants, antihistamines, and nasal irrigation. However, these treatments are limited in that they provide only partial and/or temporary relief and sometimes have untoward side-effects. For example, it is well established that the use of nasal spray decongestants, such as oxymetazoline, can lead to a phenomenon known as rebound congestion or nasal spray dependence (Ramey et al, 2006). Additionally, systemic decongestant agents, such as pseudoephedrine, have been shown to increase blood pressure and are associated with dependency (DEA Title VII of Public Law 109-177).[@CIT0006] Given the limitations of current treatment options for nasal congestion, there is a need for novel non-pharmacologic therapies, ideally ones that target the unique anatomy of the sinus system.

The objective of this study was to evaluate the performance of a novel self-applied nasal device designed to reduce nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure. The SinuSonic consists of a fully disposable medical-grade silicone nosepiece mounted to a resin body. The device is equipped with a flutter valve located at the top of the device which creates gentle, self-guided oscillating expiratory resistance. Acoustic vibration is emitted via a single circuit board speaker at the base of the device at approximately 128 Hz[@CIT0007] @ 80 decibels ([Figure 1](#F0001){ref-type="fig"}).Figure 1The SinuSonic device. Depiction of the SinuSonic nasal device. The individual depicted here was not a research subject and provided written consent for this image to be published.

The fundamental underpinnings of the device's design are based on research substantiating the therapeutic effects of positive expiratory pressure (PEP) and vibration on airway patency and mucous movement in chronic lung conditions. Although the SinuSonic device combines PEP and vibration differently than devices used for lung conditions (ie, by adding acoustic and mechanical vibration to PEP), we hypothesize that utilization of the aforementioned techniques will aid in upper airway patency and mucous movement, similar to the proven therapeutic effects for lower airway congestion. For example, a 2008 systematic review by Hristara-Papadopoulou et al found that devices that combine PEP and vibration produce statistically significant increase in lung volumes, ciliary motility, and sputum production for those with cystic fibrosis.[@CIT0008] The rationale for incorporating acoustic vibration is based on research suggesting that human humming improves sinonasal patency via increases in nitric oxide,[@CIT0004],[@CIT0009]--[@CIT0011] a smooth muscle relaxant that has anti-inflammatory and antimicrobial/fungal/viral properties.[@CIT0012]

Materials and methods {#S0002}
=====================

Participants {#S0002-S2001}
------------

A total of 14 adult participants were recruited from a private sleep disorders center. All patients were under the care of a sleep medicine specialist for a sleep condition, such as insomnia and sleep apnea but also complained of regular, daily nasal congestion for at least 2 weeks. Nasal congestion was corroborated with a Congestion Quantifier Test (COG) scores \>7.[@CIT0013] Exclusion criteria included acute or chronic rhinosinusitis, severe mechanical obstruction (eg, complete unilateral deviated septum, polyps, etc.), pregnancy, or current decongestant use. A physical exam of the nasal passages was completed to ensure the absence of severe mechanical obstruction. [Table 1](#T0001){ref-type="table"} presents sample demographics. The study protocol was approved by Advarra, a central institutional review board, for the protection of human subjects. All subjects provided written informed consent and the study was conducted in accordance with the Declaration of Helsinki. As part of the informed consent process, subjects were apprised of the principal investigator's (PI; Bogan) scientific and commercial involvement with the Sinusonic.Table 1DemographicsSample sizeN=14Sex (% female)64% (n=9)Race (% Caucasian)71% (n=10)Age (years) (min--max)52.1 (30--71)BMI (kg/m^2^)32.1 (19.9--46.1)COG-7 (min--max)18.3 (13--2)\][^1]

Procedure {#S0002-S2002}
---------

A research coordinator administered written consent, screened the patient for inclusion and administered the COG scale. If inclusion criteria were met, the patient underwent a brief examination by a study physician, including a nasal cavity examination and clinical assessment of nasal congestion severity. Next, the study coordinator administered two 10-item paper-based visual analog scale (VAS) aimed as assessing nasal congestion and ease-of-breathing ([Figure 2](#F0002){ref-type="fig"}). Each patient was instructed to circle the numeric value that corresponded to their symptom severity on the VAS scales prior to treatment. The patient was then instructed to self-apply the SinuSonic nasal mask and "breathe naturally, but with increased exhalation force \[until the flutter sound is heard\] for 2 to 5 mins, based on comfort". After device use, the patient was administered two post-VAS scales (identical to the pre-VAS measures) and instructed to circle the numeric value that corresponded to their symptoms. Next, patients rated their symptom change on a 7-item Likert Patient Global Impression of Change (PGI). The PGI was measured on the following scale: 1=very much better; 2=much better; 3=a little better; 4=no change; 5=a little worse; 6=much worse; 7=very much worse. Finally, the same physician that conducted the baseline assessment completed a Clinical Global Impression of Change (CGI). The CGI was formatted to the same Likert scale as the PGI (1=very much better; 2=much better; 3=a little better; 4=no change; 5=a little worse; 6=much worse; 7=very much worse). All physicians were blinded to the responses from the patient's self-assessment of change (PGI) to allow independent observation. In some cases, the PI of the study (who has financial interest in the study) completed the assessments.Figure 2Visual analog scale for nasal congestion (**A**) and visual analog scale for ease-of-breathing (**B**). Self-assessment measure of subjective nasal congestion and ease-of-breathing. This measure was used before and after Sinusonic, and the difference score pre-post was tabulated to analyze symptom change.

Statistical analyses {#S0002-S2003}
--------------------

Outcome variables for analysis included the difference score between pre- and post-VAS scales and the patient and clinical global impressions of change. Analyses were completed by a researcher with no commercial interest in the Sinusonic. Demographic analyses and non-parametric tests were performed with SPSS 23.0 (SPSS Inc., Chicago, IL, USA). Pre-post differences in VAS scores were assessed with Wilcoxon rank-sum analysis. Global Impressions of Change (CGI/PGI) were assessed with a one-sample Binomial test of the hypothesis that ≥75% of the sample would achieve "≥ minimal improvement" (based on expert consensus). All comparisons were one-tailed and significance was set at the 0.05 level.

Results {#S0003}
=======

As [Table 1](#T0001){ref-type="table"} illustrates, most of the sample was comprised of females (64%) and those identified as Caucasian (71%). All subjects reported severe nasal congestion (mean COG=18.3).[@CIT0013] All outcome measures were encouraging for this small pilot study of a single application of the SinuSonic in a clinic environment. Wilcoxon signed-rank tests indicated that post-test ranks were statistically improved from pre-test ranks for both VAS measures (congestion=Z=3.1, *p*=0.002; ease-of-breathing=Z=2.9, *p*=0.003). As [Figure 3](#F0003){ref-type="fig"} illustrates, all patients reported improvement in nasal congestion after a single application of the SinuSonic. Likewise, all but one subject reported improved breathing after Sinusonic use. A binomial test indicated that the proportion of patients with at least minimal improvement on CGI/PGI was higher than expected (100% actual vs expected 75% for both clinician and self-assessed, *p*=0.018; [Figure 4](#F0004){ref-type="fig"}). Importantly, no subjects reported a worsening of symptoms or discomfort from SinuSonic use.Figure 3Improvement in self-reported breathing and congestion. X-axis represents the difference score between VAS scales pre- vs post-treatment. Wilcoxon signed-rank test revealed VAS post-test ranks were statistically improved over pre-test ranks (VAS congestion Z=3.1, *p*=0.002; VAS breathing Z=2.9, *p*=0.003).**Abbreviation:** VAS, visual analog scale.Figure 4Clinical and patient global impressions of change. Binomial test -- the proportion of patients with ≥ minimal improvement on CGI/PGI was higher than expected (100% vs expected 75% for both clinician and self-assessed, *p*=0.018).**Abbreviation:** CGI/PGI, Clinical Global Impressions of Change/Patient Global Impression of Change.

Discussion and conclusion {#S0004}
=========================

This was a simple, proof-of-concept study in a small sample of treatment-seeking sleep clinic patients with self-reported chronic nasal congestion. Results from this were generally consistent with the body of literature supporting vibration and PEP on lower airway patency.[@CIT0008] That is, these limited data suggested that a single exposure to the SinuSonic in a controlled clinic environment provided short-term relief from nasal congestion symptoms with effect size in the medium-to-large range and minimal side-effects. The finding that both clinical and patient global impressions of change convergently validated self-reported symptom change was encouraging considering the absence of placebo control and small sample size.

This study had several limitations. Most obviously, this study was small, did not employ a placebo control, and observers and patients were not blinded. Thus, it is likely that some of the effects observed in this study were due to placebo effect and observer bias. Another limitation was variable therapy exposure in that patients were instructed to terminate the SinuSonic at-will. It is thus unknown the therapeutic "dose" of the SinuSonic. Despite these limitations, these data support the rationale for a larger-scaled study which will employ a sham control, more robust measures of nasal airflow change, and longer follow-up.
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